Shifting the Paradigm: The Transformative Role of Neoadjuvant Therapy in Early Breast Cancer.

paclitaxel reported in the ETNA trial failed to reach statistical significance (22.5% vs. 18.6%, respectively; OR 0.77, 95% CI, 0.52–1.13; p = 0.19) [ 91 ], which was also true for the 5-year EFS (75.6% vs. 68.1%, respectively; HR 0.83, 95% CI, 0.60–1.14; p = 0.245) [ 92 ].

also in 6,035 other papers

On the other hand, the IMpassion031 trial comparing PD-L1 inhibitor atezolizumab to placebo given with nab-paclitaxel-EC followed by atezolizumab or placebo after surgery did show a significant improvement in pCR, but it demonstrated only a nonsignificant improvement in EFS with a strong trend for OS [ 94 , 116 ].

also in 5,725 other papers